The role of loneliness and social isolation in the progression from incident type 2 diabetes mellitus (T2DM) to subsequent depression remains underexplored. Further investigation is essential to better understand how these factors influence disease progression.

This study enrolled 427,594 participants without T2DM and depression at baseline. Multistate models were employed to assess the impact of loneliness and social isolation on transitions from a healthy state to incident T2DM, then to subsequent depression, and finally to death. These associations were further examined across individuals with varying glycemic statuses, including normal glucose tolerance and prediabetes.

Over a median follow-up period of 13.66 years, 14,141 incident cases of T2DM, 1,149 subsequent cases of depression, and 33,024 death events were recorded. Loneliness and social isolation were associated with elevated risks of disease progression across most transitions. For the transition from incident T2DM to subsequent depression, the loneliness group exhibited a significantly higher risk (HR = 1.802, 95% CI: 1.521–2.135) compared to the no-loneliness group. Similarly, the most isolated group had an HR of 1.390 (95% CI: 1.185–1.632) compared to the least isolated group. Additionally, participants with prediabetes faced a higher risk of developing depression following T2DM compared to those with normal glucose tolerance. Interaction analyses revealed that employment status and history of cancer modified the association between loneliness and the transition from baseline to death.

These findings underscore the importance of targeted interventions to address loneliness and social isolation, potentially reducing the risk of disease progression and mortality in individuals with T2DM.

Schizophrenia is often a persistent mental illness characterized by cognitive deficits and altered brain network dynamics especially affecting the cortico-subcortical salience processing system. Childhood trauma has been implicated in mechanisms contributing to schizophrenia, but the role of genetic vulnerability remains unclear.

A total of 164 schizophrenia patients and 114 healthy controls were included. First, a matched subsample of 117 patients (76 with and 41 without childhood trauma), and 59 healthy controls were compared on polygenic risk scores for schizophrenia (SczPRS). SczPRS was then correlated with neurocognitive performance using a comprehensive cognitive battery (n = 147 patients) and brain-wide static and dynamic functional connectivity (sFC and dFC) using resting-state fMRI (n = 117 patients). Patients were also stratified into high-SczPRS and low-SczPRS (n = 25 each) subgroups.

Patients with childhood trauma had significantly lower SczPRS than those without. Higher Childhood Trauma Questionnaire (CTQ) scores related to lower cognitive PC score (r = −0.282, p < 0.001), but CTQ did not affect brain-wide dysconnectivity or subcortical/salience system among patients. Patients with the highest SczPRS showed lower dFC between the cingulo-opercular network and subcortical networks (F = 7.949, p = 0.007), but SczPRS did not affect cognitive performance.

Our findings reveal distinct effects of childhood trauma and polygenic risk in the neural and cognitive substrates of schizophrenia. Childhood trauma relates to poor cognitive function, while polygenic risk primarily affects salience/subcortical network dynamics. These patterns indicate that in genetically predisposed individuals who experience childhood trauma, a “double mechanistic hit” may influence the schizophrenia phenotype.

Electroconvulsive therapy (ECT) is a safe and effective medical treatment, yet provision varies internationally. We provide an up-to-date review of ECT practice in Nordic and western European countries.

European experts contributed data from peer-reviewed literature, governmental publications, unpublished administrative datasets, and hitherto unpublished surveys. The primary outcome was the number of individuals treated with ECT in each country per year. Primary analysis compared the annual treated person rate per million population in the most recent year since 2015 for which data were available. Secondary analysis compared trends in rates over 25 years, in countries for which a reliable outcome was available at two or more time points.

Across 15 countries, 12 had data meeting primary analysis criteria. Of these, all Nordic countries had annual treated patient rates per million population over 200, Italy 2.7, and other western European countries between 30 and 100. German-, Dutch-, and French-speaking countries saw increases in ECT use over 25 years, while English-speaking countries exhibited declines. Unilateral placement varied from 16% of treatments in the United Kingdom to 79% in Norway. Everywhere, most ECT was given for depressive episodes.

Although the optimal rate of use is unknown, widely differing rates across European nations suggest ECT is underused in some high-income countries, depriving patients of vital medical care. The European ECT community must support the development of reliable data collection on usage across the continent and service improvement where provision is underdeveloped, to ensure appropriate treatment is offered to all patients for whom it is indicated.

There has been growing interest in developing a clinical staging model for eating disorders (EDs). The aim of this scoping review is to investigate the extent, range, and nature of research that can inform clinical staging approaches for EDs.

This review was conducted following the Joanna Briggs Institute methodology for scoping reviews and the PRISMA extension for Scoping Reviews. A search of PubMed, PsycINFO, MEDLINE and Web of Science databases was conducted. Sixty studies were included for review, and data were extracted according to revised pre-published criteria. Studies were summarized using narrative synthesis.

Thirty-six of the included manuscripts were quantitative, 18 were qualitative, and six were conceptual/review papers. The included studies primarily focused on anorexia nervosa in white, female samples and compared only two stages of illness, equating to “early” and “longstanding” or “severe and enduring” EDs. “Middle” stages or transitions between stages were not well-defined. Stages have mostly been conceptualized using duration of illness or other behavioral or clinical parameters, with few (neuro) biological studies identified. Factors that may modify illness stage have not yet been integrated into ED staging literature.

There is growing consensus that early- and later-stage EDs have distinct characteristics and treatment requirements; however, these distinctions require clearer definition. Recommendations for future research are outlined, emphasizing integration of psychosocial and biological research, focused investigation of illness phases outside of early and longstanding phases, and evaluation of personalized, stage-based treatments. A tentative staging model for EDs is proposed.

Brain-structural and language abnormalities in people with psychotic symptoms (PSx) have long been reported. A key question is whether language alterations are a potential behavioral readout of brain cortical gray matter changes. Adding to previous evidence for this in the cases of cortical thinning and gyrification, we here used structural MRI (sMRI) to relate a complexity-theoretical metric, the Largest Lyapunov Exponent (lambda [λ]), to computational linguistic complexity metrics extracted from spontaneous speech. This study aimed to identify psychosis-related regional changes in structural complexity using λ and an explainable AI (XAI) approach. We hypothesized that altered structural complexity will relate to computational language features that have previously been shown to track brain dysconnectivity in schizophrenia in fMRI.

MRI data were acquired from 92 patients with PSx and 38 healthy controls (HCs) from the TOPSY study. Nonlinear analysis of gray matter distribution was performed by extracting the λ for gray matter voxels. XAI was employed to identify the voxels contributing significantly to classifying PSx against HCs. Finally, the brain voxels’ contribution was tested for associations with word perplexity and syntactic and semantic complexity metrics, from spontaneous speech as obtained from picture descriptions, and with clinical symptom severity (SOFAS and PANSS scores).

The classification framework resulted in a balanced accuracy of 75.9%. The voxels contributing most to the classification decision were located in the temporal lobe, cingulum, angular, lingual, calcarine, occipital, fusiform, and parietal cortices, and parts of the cerebellum and vermis. Structural complexity in these regions was significantly associated with clinical variables (SOFAS and PANSS), word perplexity, and lexical diversity.

We present a new analytical framework using spatial series extracted from sMRI, demonstrating that alterations in structural complexity are an identifiable feature of psychosis, which co-vary with probabilistic and structural changes in speech as a behavioral readout.

The relationship among food insecurity, financial strain, and depression and anxiety is complex and likely bidirectional, yet most studies have examined this relationship unidirectionally and cross-sectionally. Our study investigates the longitudinal bidirectional relationship among depression and/or anxiety and food insecurity and financial strain.

Food insecurity and financial strain were measured at four waves across 13 years in the NESDA cohort. Clinical diagnoses of depression and anxiety were determined using the CIDI. Symptom severity was assessed using the IDS-SR and BAI. Lagged multilevel models examined whether food insecurity and financial strain predicted changes in depression and/or anxiety and vice versa. All models adjusted for age, sex, education, household income contributors, and prior outcome levels.

Among 2,567 individuals (mean age 42.4 years (SD 13.2), 34.6% women), higher food insecurity and financial strain significantly predicted increased odds of onset of depressive disorders (OR = 2.12, 95% CI: 1.43–3.15 and OR = 1.92, 95% CI: 1.51–2.45, respectively), and greater depressive symptom severity at the next wave (p’s for trend < .001 and p = .001, respectively). Associations with anxiety disorders and symptom severity were weaker. Conversely, depressive disorders and symptoms predicted higher subsequent food insecurity and financial strain, whereas anxiety symptoms did not.

Our findings support a bidirectional temporal association among food insecurity, financial strain and depression, with weaker evidence for anxiety. Approaches that address financial hardship and mental health may be beneficial. Further long-term studies in diverse populations are needed to clarify mechanisms linking financial insecurity with mental health and to guide effective intervention development.

Cannabinoids are increasingly discussed as adjuncts in addiction treatment, yet whether they improve clinically meaningful substance use disorder (SUD) outcomes beyond short-term symptom relief is unresolved. We determined whether cannabinoid exposure confers directional efficacy across opioid, alcohol, cocaine, tobacco, and methamphetamine use disorders, distinguishing symptomatic targets from sustained therapeutic outcomes.

PubMed and Embase (1975–2025) were searched for human studies evaluating cannabinoid exposure in relation to SUD outcomes. Two reviewers independently screened and extracted data. Risk of bias was assessed using RoB 2 for randomized controlled trials (RCTs), ROBINS-I for cohort studies, and JBI checklists for cross-sectional, case, and qualitative designs. Six prespecified endpoints (treatment retention, relapse, abstinence, craving, withdrawal severity, consumption) were mapped to each target SUD. Following Synthesis Without Meta-analysis (SWiM) guidance, structured narrative synthesis used a design-based weighting scheme (RCT 1.00 to qualitative 0.25). PROSPERO: CRD420251151193.

Ninety-seven studies (41,954 participants) contributed 195 endpoint instances: 89 Beneficial (45.6%), 80 No Significant Effect (41.0%), 12 Mixed/Partial (6.2%), and 14 Harmful/Inferior (7.2%). Short-term symptom targets accounted for most Beneficial findings (76.4%). Sustained outcomes were predominantly No Significant Effect, most pronounced in opioid use disorder. Beneficial symptom findings derived overwhelmingly from weaker study designs (craving 81.5%; withdrawal severity 85.7%; consumption 80.0%).

Cannabinoids confer short-horizon symptomatic benefits but do not demonstrate efficacy for sustained abstinence, relapse prevention, or retention, most clearly in opioid use disorder, where evidence is strongest. Findings for other disorders remain preliminary. Adequately powered adjunctive randomized trials with biochemically verified endpoints are needed.

Early adolescence marks a critical period for the onset of psychiatric symptoms, with 50% of mental disorders emerging before age 18. Recent evidence points to individuals being born preterm and/or with low birth weight (henceforth, PTB) having an increased risk of developing mental disorders in adolescence. Surprisingly, existing early detection and intervention strategies in adolescence are not tailored to PTB needs and profiles. The previous use of several disorder-specific instruments complicates unified, efficient screening.

We analyzed data on the frequency of experiencing mental health challenges from 225 adolescents aged 10-14 years (M = 12.03 years) who were born very PTB (M = 28.03 weeks, M = 999.62 g) to test the applicability of the diagnostic system for mental disorders for children and adolescents – III (DISYPS-III) to PTB adolescents.

A confirmatory factor analysis replicated the DISYPS-III’s factorial structure and internal consistency for 10- to 14-year-old PTB adolescents. Overall, PTB adolescents reported significantly more mental health challenges than the DISYPS-III community norm sample. The instrument’s transdiagnostic scales provided a better relative fit to these challenges compared to the disorder-specific scales. Results also replicated specific findings of mental health challenges from other PTB cohorts and countries, such as a higher number of comorbidities in adolescents officially diagnosed with the inattentive presentation (ADD) of ADHD.

These findings of an elevated psychological burden suggest a need for structured PTB screening of long-term mental health outcomes in adolescence that also includes 10-year-old PTB individuals, with the DISYPS-III being a suitable screening instrument.

Bipolar disorder (BD) is frequently misdiagnosed as major depressive disorder (MDD), with diagnostic delays averaging 6–10 years leading to suboptimal treatment and poorer outcomes. Early identification of patients at risk for diagnostic conversion remains a critical clinical priority. We aimed to identify clinical predictors of BD conversion in a large population-based cohort and develop a clinically applicable prediction model.

We conducted a retrospective cohort study using electronic health records from the Catalan PADRIS-PRESTO database (2010–2019). Patients aged ≥18 years with incident MDD diagnosed in specialized mental health services (2015–2019) were followed until BD diagnosis, death, or study end. Time-varying Cox regression addressed proportional hazards violations, with competing risks analysis accounting for mortality.

Among 52,001 patients (median follow-up 4.0 years), 3,958 (7.61%) converted to BD. Psychotic features emerged as the strongest predictor (HR = 3.18, 95% CI: 2.92–3.45, E-value = 5.82), with consistent effects across follow-up. Anxiety disorders showed time-varying protection (baseline HR = 0.41, 95% CI: 0.35–0.48) that attenuated over time (interaction HR = 1.30 per period). The time-varying model achieved good discrimination (C-index = 0.745). Machine learning validation confirmed predictor importance rankings (Spearman r = 0.87).

Psychotic features during depressive episodes robustly predict BD conversion, warranting enhanced clinical monitoring. Our time-varying prediction model using routinely collected clinical data enables early risk stratification to guide diagnostic vigilance and treatment decisions.

Real-world data for intranasal esketamine in treatment-resistant depression (TRD) are needed to characterize effectiveness, suicidality, and tolerability in routine care. We evaluated induction phase outcomes in outpatients with TRD treated at the University Hospital Vienna.

This retrospective single-center registry study included adults with TRD initiating supervised intranasal esketamine. The primary endpoint was the change in clinician-rated depressive symptom severity (MADRS) from the pre-treatment (PV) to the end of induction (EOI) visit. MADRS scores across baseline (BL), PV, and EOI were analyzed using a mixed model for repeated measures. Secondary outcomes included MADRS three-factor change, self-rated depression score trajectories (PHQ-9), response/remission rates, suicidal ideation, and tolerability.

Of 229 screened patients, 176 initiated esketamine and 156 completed induction. MADRS at BL was 31.5 (SD 6.4), PHQ-9 was 18.5 (SD 4.7). In the primary model, adjusted mean MADRS was 30.3 at PV and 17.7 at EOI, yielding a change of −12.5 points (95%CI −14.1 to −11.0; p < 0.001; Hedges’ g = 1.8). All MADRS factors improved, with the largest reduction in the affective–anhedonic domain. PHQ-9 decreased steadily across treatments. Remission was 27.2% and response 57.4% at EOI. Suicidal ideation decreased significantly; no suicide or serious self-harm occurred during induction. Adverse events (AEs) were recorded in 34.7%, with AE-related discontinuation in 3.4%.

Esketamine induction was associated with marked improvement in depressive symptoms and suicidality, with acceptable tolerability under supervised administration. Longer-term registry follow-up and controlled comparative studies are needed to further define the benefit–risk profile beyond induction phase.

Narcissistic Personality Disorder (NPD) involves disturbances in self-regulation, interpersonal functioning, and personality organization. Although traditionally characterized by grandiosity, contemporary models suggest that grandiose self-states coexist with vulnerable features such as shame, emotional dysregulation, and hypersensitivity to rejection. Recent evidence indicates that metacognitive impairments may underlie both grandiose and vulnerable narcissistic presentations; however, no study has examined how metacognition interacts with personality traits and interpersonal difficulties within an integrated system.

A cross-sectional network analysis was conducted on 287 patients with NPD. Measures included the Metacognition Assessment Interview, the Pathological Narcissism Inventory, the Personality Inventory for DSM-5 (PID-5), the Inventory of Interpersonal Problems, and SCL-90-R Depression. A Gaussian graphical model with LASSO regularization was estimated, and expected influence was used as the primary index of node centrality. Network accuracy and stability were assessed through bootstrapping procedures.

Narcissistic vulnerability was the most central node, followed by interpersonal sensitivity and metacognitive integration. Narcissistic vulnerability showed strong associations with PID-5 Negative Affectivity and Detachment, whereas narcissistic grandiosity was related to PID-5 Antagonism. Metacognitive integration occupied a central position, linking maladaptive traits and interpersonal distress. Network stability indices indicated good reliability.

Findings suggest that narcissistic vulnerability and interpersonal hypersensitivity are central aspects of dysfunction in NPD, whereas metacognitive integration appears closely associated with the organization of psychological processes within the network. Although causal inferences cannot be drawn, the results are consistent with theoretical models underlying Metacognitive Interpersonal Therapy (MIT), supporting the potential relevance of targeting integrative metacognitive capacities in NPD treatment.

Previous research has demonstrated the positive impact of early remission on disease trajectory for patients with major depressive disorder. However, there is a paucity of literature assessing the response trajectory for patients with treatment resistant depression (TRD). These analyses investigated patient outcome trajectories to Week 32, including the relationship between short- and long-term outcomes with esketamine nasal spray (ESK-NS) treatment and symptom resolution.

ESCAPE-TRD (NCT04338321), a randomized, open-label, phase IIIb study, evaluated the efficacy and safety of ESK-NS versus quetiapine extended release (QTP-XR) in patients with TRD. Rater-blinded Montgomery-Åsberg Depression Rating Scale (MADRS) total score was used to assess depressive symptoms and the trajectory of patient responses to Week 32. For ESK-NS versus QTP-XR, time to symptom resolution across MADRS items was evaluated using Kaplan–Meier analyses.

Of 676 patients, 336 and 340 were randomized to ESK-NS and QTP-XR, respectively. Most ESK-NS-treated patients achieved continuously improved outcomes to Week 32; early response was associated with better long-term outcomes. Among patients who achieved Week 4 response, 89.6% achieved remission at any point from Week 4 to 32; 78.3% of Week 8 responders achieved remission at any point from Week 8 to 32. Greater and earlier symptom resolution was observed with ESK-NS versus QTP-XR across most MADRS items.

Most ESK-NS-treated patients with TRD showed continuous improvements over time, with short-term response associated with better long-term outcomes. Long-term improvements were observed even among partial/minimal early responders, reinforcing the value of longer treatment. ESK-NS had a positive impact across the full spectrum of MADRS-assessed symptoms.

Gaming disorder (GD), i.e., persistent problematic gaming with clinically significant impairment, is a growing concern; however, estimates of GD in representative adolescent samples are limited. This study aimed to examine GD prevalence, incidence, persistence, and risk factors for different epidemiological parameters across 6 years, covering pre- to post-COVID-19 pandemic.

Population-based longitudinal data, including 3358 German adolescents, were collected annually from 2019 to 2024 using online surveys. GD prevalence estimates were assessed by standardized International Classification of Diseases (ICD-11)-based self-report questionnaires. Between-wave persistence and incidence of GD, sociodemographic data, gaming time, and stress perception were measured. Risk factors for incidence and persistence of GD were examined using generalized-estimating equation (GEE) models.

GD prevalence doubled from 2.9% in 2019 to 6.5% in 2023 and remained above prepandemic levels in 2024 (3.9%). Males showed higher prevalence estimates compared to females across most waves, and prevalence peaked in 2023 (8%). For females, GD prevalence doubled between 2019 (1.7%) and 2020 (3.4%), peaked in 2022 (6.1%), and declined thereafter. The incidence of GD increased during the pandemic. According to GEE models, male sex, higher perceived stress, and longer gaming times were risk factors for GD incidence; older age and higher education were protective factors. The persistence of GD reached its peak in 2020 (36.2%). Significant risk factors for GD persistence were higher stress perception and longer gaming time.

Prevalence and incidence rates indicate that GD continues to be a significant concern, and pandemic-related increases affected both males and females. Prevention and intervention programs should target identified risk groups.

Gaming disorder (GD) is recognized by the WHO as a behavioral addiction, yet research remains predominantly men-centric. This study explores the experiences of women gamers, their perceptions of GD, and the barriers women face in accessing care.

Semi-structured interviews were conducted with seven participants identifying as women (six cisgender women and one transgender woman) aged 21–26 years old, in France and Switzerland. Inductive reflexive thematic analysis was used to identify women’s experiences of gaming behavior, stigma, and help-seeking.

Participants reported diverse gaming behaviors, with preferences for narrative-driven games (e.g., RPG and simulations). Stigma, lack of self-awareness, limited self-recognition of problematic gaming, and broader societal misconceptions emerged as significant barriers to recognizing GD as a potential clinical issue warranting help-seeking. None had sought professional care for GD, citing gendered stereotypes and diagnostic biases as key deterrents.

The study highlights the need for women-centered diagnostic tools, clinical approaches, targeted awareness campaigns, and flexible support systems for women with GD. Future research should prioritize larger, diverse samples and intersectional approaches.

Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates.

In this prospective multicenter study, 60 patients with TRD initiating intranasal esketamine augmentation were assessed at baseline, Month 1, Month 3, and Month 6 using the Montgomery-Åsberg Depression Rating Scale (MADRS) and Sheehan Disability Scale (SDS). Mixed-effects models, Turnbull interval-censored time-to-remission analysis, logistic regression, and ROC analyses were performed.

MADRS and SDS improved significantly at all follow-up time points (p < 0.001). At Month 6, symptomatic response and remission rates were 78.3 and 46.7%, while functional response and remission rates were 78.3 and 33.3%, respectively. Turnbull estimates showed cumulative functional remission rates of 5.0, 15.0, and 33.3% at Months 1, 3, and 6, respectively. MADRS-SDS correlations decreased over time, supporting partial symptomatic-functional dissociation. Higher baseline SDS (OR = 0.73, 95% CI: 0.59–0.89) and more previous antidepressant trials (ADTs; OR = 0.53, 95% CI: 0.35–0.82) were associated with lower odds of Month 6 functional remission; bootstrap internal validation supported coefficient stability. ROC-derived thresholds were considered sample-dependent and not clinically validated. Cumulative esketamine dosage was associated with functional response but not remission.

Depressive symptoms and functioning improved progressively over 6 months during esketamine treatment in routine clinical care. Functional remission followed a slower trajectory than symptomatic remission and had partly distinct correlates, supporting functional monitoring as a distinct TRD outcome.

The development of cognitive impairment (CI) is a frequent and debilitating consequence of COVID-19 and can persist for more than 1 year after the acute infection stage. Previous neuroimaging studies in COVID-19 survivors with CI have revealed widespread alterations in functional connectivity (FC), particularly within fronto-parietal circuits and subcortical nuclei such as the hippocampus, basal ganglia, and thalamus. This study focuses on neural correlates of CI in subjects who recovered from COVID-19 and the relationship between FC patterns and discrete cognitive domains.

Resting-state functional MRI data from 136 subjects were analyzed using a ROI-to-ROI approach across 246 brain regions derived from the Human Brainnetome Atlas. Group comparisons were performed based on the presence or absence of CI, and correlation analyses were conducted between FC and scores obtained from a comprehensive neuropsychological test battery.

Whole-brain FC showed no difference between patients with and without CI. In the whole study sample, hypoconnectivity between two basal ganglia regions and two frontal motor regions was associated with impaired performance in the cognitive domain “Reasoning and Problem-Solving,” while hyperconnectivity between the prefrontal thalamus and the postcentral gyrus was associated with impaired performance in the same cognitive domain.

Our findings indicate that FC alterations within the cortico-striatal and thalamo-cortical circuits may subtend deficits in higher-order executive functions in post-COVID-19 patients and highlight the importance of examining discrete cognitive domains in relation to brain connectivity.

Treatment-Resistant Late-Life Depression (TRLLD) represents a significant clinical and research challenge. Studies on TRLLD use heterogeneous diagnostic criteria limiting the interpretation of results and the development of clinical guidelines.

This study aimed to establish expert consensus on the core components and definition of TRLLD through a Delphi process conducted by a European Task Force of clinicians and researchers with experience in late-life depression.

We conducted an electronic Delphi study with 30 European experts to identify key definitional elements of TRLLD. In the 1st survey round (SR), participants responded to open-ended questions on definitions of TRLLD. Responses informed the development of 70 structured items for 2nd SR, involving 58 closed (yes/no) items and 12 multiple-choice questions across six domains: symptom presentation, cognitive impairment, comorbidities, pharmacotherapy, treatment adherence, and psychosocial factors. Consensus was defined as ≥70% agreement. In 3rd SR, participants reviewed comments and validated the final categorical definition, the operational staging model, and the derived decision algorithm for TRLLD.

Consensus was reached for 72.4% of the 58 closed items. Experts agreed that the categorical definition of TRLLD should correspond to major depressive disorder in individuals aged ≥65 years who show insufficient response to two adequate antidepressant treatments, in the absence of dementia and medical conditions that could account for depressive symptoms. An operational staging model and decision-making algorithm were developed from consensus items.

This study provides the first European consensus definition of TRLLD and highlights the need for age-adapted diagnostic criteria that reflect the clinical complexity of depression in older adults.

While both evidence-based medicine as well as personalized patient-centered medicine are glorified, clinical practice seems to be only partially influenced by guidelines or by patients’ views. Against this background, shared decision-making (SDM) became a hype but remains an ill-defined concept: it can be considered as an umbrella concept covering therapeutic alliance, physician and patient preferences, information giving, information retrieving, information receiving, patient involvement in goal setting, decision-making, and treatment choice.

A narrative review based on a literature search in PubMed and PsycINFO.

SDM in depression should move away from an ethical imperative where “one size fits all” toward a personalized approach, tailoring the medical encounter to the physician’s and patient’s expectations (knowledge, need for knowledge, and desire for degree of SDM) and to the patient’s clinical status. SDM cannot be conceived as a “snapshot” since it is a dynamic process where adjustments should be made depending on the growth of the doctor–patient alliance, the changes in expectations, and the changes in clinical status. The clinician should be more aware of barriers to effective implementation of SDM in him or herself, in the patient. The different definitions of SDM and the many reported SDM interventions (having different ingredients) hamper final conclusions on the effect of SDM on outcomes.

This narrative review aims to critically examine SDM in depression and proposes to conceptualize it as a dynamic, relational, and personalized process rather than a universal ethical standard.